Erratum: Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials (The Lancet (2015) 385(9979) (1729–1737) (S0140673614624491) (10.1016/S0140-6736(14)62449-1));Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials

The Lancet

Volumn 385, Issue 9979, 2015, Pages 1729-1737

  Dobson, Joanna ^a   Whitley, Richard J ^b   Pocock, Stuart ^a   Monto, Arnold S ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; ANTIVIRUS AGENT;

ADULT; ANTIBODY TITER; ARTICLE; BRONCHITIS; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEART DISEASE; HIGH RISK PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASONAL INFLUENZA; VOMITING; AGED; DOUBLE BLIND PROCEDURE; INFLUENZA, HUMAN; MIDDLE AGED; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; HUMANS; INFLUENZA, HUMAN; MIDDLE AGED; OSELTAMIVIR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929029181     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62411-9     Document Type: Erratum

References (31)

1. M von Itzstein, WY Wu, GB Kok et al. Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 363 1993 418 423
2. PM Colman, JN Varghese, WG Laver Structure of the catalytic and antigenic sites in influenza virus neuraminidase Nature 303 1983 41 44
3. JN Varghese, JL McKimm-Breschkin, JB Caldwell, AA Kortt, PM Colman The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor Proteins 14 1992 327 332
4. FG Hayden Perspectives on antiviral use during pandemic influenza Philos Trans R Soc Lond B Biol Sci 356 2001 1877 1884
5. AS Monto The threat of an avian influenza pandemic N Engl J Med 352 2005 323 325
6. T Jefferson, M Jones, P Doshi, EA Spencer, I Onakpoya, CJ Heneghan Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments BMJ 348 2014 g2545
7. Treanor JJ. Reduction in the symptoms and complications of influenza A and B in patients treated with oseltamivir. Presented at: the 38th Annual Meeting of the Infectious Disease Society of America; September 7-10, 2000, New Orleans, La. Abstract 611.
8. C Martin, P Mahoney, P Ward Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications AD Osterhaus N Cox AW Hampson Proceedings of the World Congress on Options for the Control of Influenza IV; September 23-28, 2000; Crete, Greece. International Congress Series 1219 2001 Excerpta Medica New York, NY 807 811
9. KG Nicholson, FY Aoki, AD Osterhaus et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group Lancet 355 2000 1845 1850
10. S Kashiwagi, S Kudoh, A Watanabe, I Yoshimura Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza: placebo-controlled double-blind multicenter phase III trial [in Japanese] Kansenshogaku Zasshi [Jpn J Infect Dis] 74 2000 1044 1061
11. JJ Treanor, FG Hayden, PS Vrooman et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza JAMA 283 2000 1016 1024
12. Robson R, Saiedabadi N, Ward P. Oral oseltamivir reduces the duration of influenza illness by 2·7 days in previously healthy adults. Presented at: the 9th International Congress on Infectious Diseases; April 10-13, 2000; Buenos Aires, Argentina. Abstract 80.019.
13. L Li, B Cai, M Wang, Y Zhu A double-blind, randomised, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China Chin Med J (Engl) 116 2003 44 48
14. NJ Dharan, AM Fry, BA Kieke et al. Clinical and virologic outcomes in patients with oseltamivir-resistant seasonal influenza A (H1N1) infections: results from a clinical trial Influenza Other Respir Viruses 6 2012 153 158
15. D Collett Modelling survival data in medical research 2nd edn. 2003 Chapman & Hall/CRC Boca Raton
16. MJ Bradburn, JJ Deeks, JA Berlin, AR Localio Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events Stat Med 26 2007 53 77
17. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. Updated March 2011. http://handbook.cochrane.org/ (accessed Jan 27, 2015).
18. DG Altman Confidence intervals for the number needed to treat BMJ 317 1998 1309 1312
19. SG Muthuri, PR Myles, S Venkatesan, J Leonardi-Bee, JS Nguyen-Van-Tam Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients J Infect Dis 207 2013 553 563
20. J Hsu, N Santesso, R Mustafa et al. Antivirals for treatment of influenza. A systematic review and meta-analysis of observational studies Ann Intern Med 156 2012 512 524
21. M Egger, G Davey Smith, AG Altman Systematic reviews in healthcare: meta-analysis in context 2nd edn. 2001 BMJ Publishing Group London
22. RJ Whitley, FG Hayden, KS Reisinger et al. Oral oseltamivir treatment of influenza in children Pediatr Infect Dis J 20 2001 127 133
23. SL Johnston, F Ferrero, ML Garcia, R Dutkowski Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma Pediatr Infect Dis J 24 2005 225 232
24. AM Fry, D Goswami, K Nahar et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial Lancet Infect Dis 14 2014 109 118
25. S Heinonen, H Silvennoinen, P Lehtinen et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomised controlled trial Clin Infect Dis 51 2010 887 894
26. USA Center for Drug Evaluation and Research (CDER). Guidance for industry. Influenza: developing drugs for treatment and/or prophylaxis 2011 US Department of Health and Human Services, Food and Drug Administration
27. SG Muthuri, S Venkatesan, PR Myles et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data Lancet Respir Med 2 2014 395 404
28. MA Hernán, M Lipsitch Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomised clinical trials Clin Infect Dis 53 2011 277 279
29. M Lipsitch, MA Hernan Oseltamivir effect on antibiotic-treated lower respiratory tract complications in virologically positive randomized trial participants Clin Infect Dis 57 2013 1368 1369
30. L Kaiser, C Wat, T Mills, P Mahoney, P Ward, F Hayden Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations Arch Intern Med 163 2003 1667 1672
31. L Kaiser, ON Keene, JMJ Hammond, M Elliot, FG Hayden Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults Arch Intern Med 160 2000 3234 3240